suramin has been researched along with Proteinuria in 8 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was carried out to evaluate if inhibited angiogenesis by Suramin injections in early pregnancy may cause a condition resembling pre-eclampsia in rats." | 7.73 | Placental dysfunction in Suramin-treated rats--a new model for pre-eclampsia. ( Eriksson, UJ; Jansson, L; Lindeberg, S; Naessén, T; Nash, P; Olovsson, M; Wentzel, P, 2005) |
| "Suramin is a compound that inhibits the interaction of several cytokines and growth factors with their receptors, but whether suramin inhibits the progression of renal fibrosis is unknown." | 5.37 | Suramin inhibits renal fibrosis in chronic kidney disease. ( Liu, N; Pang, M; Ponnusamy, M; Tolbert, E; Yan, H; Zhuang, S, 2011) |
| " This study was carried out to evaluate if inhibited angiogenesis by Suramin injections in early pregnancy may cause a condition resembling pre-eclampsia in rats." | 3.73 | Placental dysfunction in Suramin-treated rats--a new model for pre-eclampsia. ( Eriksson, UJ; Jansson, L; Lindeberg, S; Naessén, T; Nash, P; Olovsson, M; Wentzel, P, 2005) |
| " One such compound, suramin, was shown to be an effective inhibitor of PCA and the proteinuria manifestation of EGN while not affecting antibody fixation to tissue or histamine-mediated skin reaction." | 3.66 | Inhibition of immune complex-mediated activation of complement. Effects of agents modulating activation of, and the activated C1 complex. ( Fletcher, DS; Lin, TY, 1980) |
| "Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects." | 2.71 | Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. ( Banks, RE; Cranston, D; Crew, J; Harris, AL; Joel, SP; Jones, A; Le Monnier, K; Ord, JJ; Roberts, IS; Rogers, MA; Streeter, E, 2005) |
| "We conclude that in preeclampsia, the decrease of relaxation responses and the decrease of cGMP content could be due to the reduction in stimulation of sGC and the decrease in cGMP levels." | 1.39 | Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model. ( Bagcivan, I; Karadas, B; Parlak, M; Temiz, TK; Turgut, B; Turgut, NH, 2013) |
| "Suramin is a compound that inhibits the interaction of several cytokines and growth factors with their receptors, but whether suramin inhibits the progression of renal fibrosis is unknown." | 1.37 | Suramin inhibits renal fibrosis in chronic kidney disease. ( Liu, N; Pang, M; Ponnusamy, M; Tolbert, E; Yan, H; Zhuang, S, 2011) |
| "Suramin sodium is an aromatic polysulfonated compound that was originally introduced as an antiparasitic agent in the 1920s." | 1.28 | A pilot study of suramin in the treatment of metastatic renal cell carcinoma. ( Cooper, MR; Danesi, R; La Rocca, RV; Myers, CE; Stein, CA; Uhrich, M, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turgut, NH | 2 |
| Temiz, TK | 2 |
| Turgut, B | 2 |
| Karadas, B | 2 |
| Parlak, M | 1 |
| Bagcivan, I | 2 |
| Gulturk, S | 1 |
| Liu, N | 1 |
| Tolbert, E | 1 |
| Pang, M | 1 |
| Ponnusamy, M | 1 |
| Yan, H | 1 |
| Zhuang, S | 1 |
| Nash, P | 1 |
| Wentzel, P | 1 |
| Lindeberg, S | 1 |
| Naessén, T | 1 |
| Jansson, L | 1 |
| Olovsson, M | 1 |
| Eriksson, UJ | 1 |
| Ord, JJ | 1 |
| Streeter, E | 1 |
| Jones, A | 1 |
| Le Monnier, K | 1 |
| Cranston, D | 1 |
| Crew, J | 1 |
| Joel, SP | 1 |
| Rogers, MA | 1 |
| Banks, RE | 1 |
| Roberts, IS | 1 |
| Harris, AL | 1 |
| Fletcher, DS | 1 |
| Lin, TY | 1 |
| La Rocca, RV | 1 |
| Stein, CA | 1 |
| Danesi, R | 1 |
| Cooper, MR | 1 |
| Uhrich, M | 1 |
| Myers, CE | 1 |
| Kennedy, P | 1 |
| Terry, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer[NCT00006476] | Phase 1 | 15 participants (Anticipated) | Interventional | 2000-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for suramin and Proteinuria
| Article | Year |
|---|---|
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitiona | 2005 |
7 other studies available for suramin and Proteinuria
| Article | Year |
|---|---|
Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Cyclic GMP; Disease Models, Animal; Dose-Response Relation | 2013 |
The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; | 2008 |
Suramin inhibits renal fibrosis in chronic kidney disease.
Topics: Actins; Animals; Antineoplastic Agents; Cells, Cultured; Chronic Disease; Disease Models, Animal; Di | 2011 |
Placental dysfunction in Suramin-treated rats--a new model for pre-eclampsia.
Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Disease Models, Animal; Electrolytes; Endothelin-1 | 2005 |
Inhibition of immune complex-mediated activation of complement. Effects of agents modulating activation of, and the activated C1 complex.
Topics: Animals; Antigen-Antibody Complex; Complement Activating Enzymes; Complement Activation; Complement | 1980 |
A pilot study of suramin in the treatment of metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Fever; Gastrointestinal Diseases; Hematologic Diseases; | 1991 |
Suramin induced amino-aciduria.
Topics: Humans; Onchocerciasis; Phosphates; Proteinuria; Renal Aminoacidurias; Suramin | 1972 |